PRECISIONS is rooted in a plausible mechanism that links dysregulated innate immunity to pulmonary fibrosis based on pre-clinical models, identification of genes critical in regulating immunity (i.e., TOLLIP), and pharmaco-genetic studies that suggest a potential benefit of NAC in IPF patients with the TOLLIP TT genotype. The gene discussed is TOLLIP; the disease is idiopathic pulmonary fibrosis.